Literature DB >> 14620395

Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem.

Jeremy M T Hamilton-Miller1.   

Abstract

Many beta-lactam antimicrobials were developed between the 1960s and 1980s, with continuing development driven by the emergence of microbial resistance. Penems form a discrete class of beta-lactams that comprises structural hybrids of penicillins (penams) and cephalosporins (cephems). The chemistry and microbiology of the representative penems MEN 10700, ritipenem, CGP 31608, sulopenem, BRL 42715, and faropenem are reviewed. Particular emphasis is placed on faropenem, which is in late clinical development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14620395     DOI: 10.1592/phco.23.14.1497.31937

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.

Authors:  Neeraj Dhar; Vincent Dubée; Lluis Ballell; Guillaume Cuinet; Jean-Emmanuel Hugonnet; François Signorino-Gelo; David Barros; Michel Arthur; John D McKinney
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

2.  Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes.

Authors:  Kristine M Hujer; Nashaat S Hamza; Andrea M Hujer; Federico Perez; Marion S Helfand; Christopher R Bethel; Jodi M Thomson; Vernon E Anderson; Miriam Barlow; Louis B Rice; Fred C Tenover; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 3.  Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Authors:  George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2022-03-16       Impact factor: 9.546

Review 4.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge.

Authors:  Sumitha Nayak; Uday Pai; Amita Birla
Journal:  Cureus       Date:  2022-04-25

6.  Newer antibacterials in therapy and clinical trials.

Authors:  Simi S Paknikar; Sarala Narayana
Journal:  N Am J Med Sci       Date:  2012-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.